Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

crisaborole ointment

A topical ointment formulation composed of crisaborole, a boron-containing phosphodiesterase 4 (PDE4) inhibitor, with potential immunomodulating activity. Upon topical administration of the crisaborole ointment to the affected area(s), crisaborole targets, binds to and inhibits PDE4, which increases intracellular cyclic adenosine monophosphate (cAMP) levels. This decreases inflammation in the skin. PDE4 inhibition may reduce cetuximab-related skin toxicity and atopic dermatitis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Eucrisa
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search